Sign Up | Log In | What is SocialPicks?

Vertex Pharmaceuticals Inc (VRTX) Trade Now » Rate VRTX - Discuss VRTX - Add to Watch List

Sector: Healthcare > Industry: Biotechnology & Drugs

SocialPicks Sentiment:

** v.s. other stocks

This Quarter's Sentiment:

All:

75.0%

Top:

100.0%

Rate VRTX:

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

VRTX: Bull or Bear?

From: SocialPicks | Blogsphere | All

From the Blogosphere

This Week's Insider Buys

Autonation Inc (AN)= $ 9,778,491
General Growth Properties Inc (GGP)= $ 6,088,897
Opko Health Inc (OPK) = $5,695,800
Align Technology Inc (ALGN )= $3,882,138
Hugoton Royalty Trust (HGT)= $ 3,818,759
Colonial Bancgroup Inc (CNB)= $3,442,914
Amicus Therapeutics Inc (FOLD) = $3,169,470
Fidelity National Info Services Inc Ga (FIS)= $2,080,400
Smithfield Foods Inc (SFD) = $2,056,643
Vertex Pharmaceuticals Inc (VRTX)= $ 1,526,544

? Grab this Headline Animator

Visit the ValuePlays Bookstore for Great Investing Books

Continue reading »

By Todd Sullivan (+0.00%) 02/24/08

Comment

NASDAQ Technical Picture - Bear Market Bounce

5 %

38% Fibonacci retracement of the NASDAQ's last leg down was a cue for profit taking. Friday's gap up due to MSFT earnings was a perfect exit strategy because it brought us all the way back to the last breakdown point. Declining volume on this week's bounce is typical of a bear market bounce.

Friday's bearish engulfing bar implies further weakness ahead of the FED on Wednesday. The economic calendar is loaded this week starting with New Home sales tomorrow at 10:00.

Earnings this week from Internet heavyweights - YHOO, AMZN and GOOG.

<>Stocks over $5 posting the largest percentage loss over the l...

Continue reading »

By Trading Goddess (-46.13% risk: aggressive) 01/28/08

Comment

Friday's Upgrades and Downgrades

2 %

<>
UPGRADES
St. Jude Medical (STJ)= Stanford Research Hold » Buy
Endo Pharm (END)=P Pacific Growth Equities Neutral » Buy
Informatica (INFA)= Pacific Growth Equities Neutral » Buy
Netflix (NFLX)= Utendahl Under-weight » Equal-weight
Quintana Maritime (QMAR)= Ferris Baker Watts Neutral » Buy
F5 Networks (FFIV)= Ferris Baker Watts Neutral » Buy
ITT Educational (ESI)= Barrington Research Mkt Perform » Outperform
Varian Medical (VAR)= Leerink Swann Mkt Perform » Outperform
Entercom ETM (SMH)= Capital Sell » Neutral
QLT Inc (QLTI)= Caris & Company Average...

Continue reading »

By Todd Sullivan (-25.49% risk: aggressive) 01/25/08

Comment

Friday's Upgrades and Downgrades

Continue reading »

By Todd Sullivan (+0.00%) 01/25/08

Comment

January 2008 Performance Review

52%

It is time again to review past picks and to learn about my mistakes.

The table below includes a list of my historical picks.

Click here for a link to this table in Google Docs for a better view

ARNA and ALTU stand out as worst performing picks. Interestingly they are both small cap picks, so this drop is not so unexpected. I am removing ALTU from my picks due to current conflicts of interest. ARNA ( link to original post) has suffered because they have not announced a partner yet for its weight loss drug Lorcaserin. This is probably because the pharmaceutical industry thinks that weight los...

Continue reading »

By jmho (-9.20% risk: aggressive) 01/20/08

Comment

« previous
1
2
3
4
5
6
7
8
9
next »

ROCK-STAR INVESTORS

Rank	Name	Sharpe Ratio	Avg Return	Followers
1	noshoes	21.10	+34.25%	381
2	Gerald Greene	18.14	+72.34%	210
3	stockmarketfunding.com	17.66	+25.65%	55
4	akiralegrand	13.47	+14.32%	61
5	anup2104	12.13	+76.91%	39

... more »

POPULAR STOCKS

Symbol	Company Name	Sentiment
CSCO	Cisco Systems Inc
GS	Goldman Sachs Group Inc The
LEH	Lehman Brothers Holdings Inc
AMD	Advanced Micro Devices Inc
F	Ford Motor Company
RIO	Companhia Vale Do Rio Doce

... more »

TODAY'S HEADLINES

LDK Solar's Growth Potential Offset by Gross Margin Pressure
by Paul Cheung (Zacks.com) about LDK

Cisco Systems Still a Wait and See
by Thomas Catino (Ant & Sons) about CSCO

The Merrill Lynch Diet: Starving Shareholders
by Zack Miller (BloggingStocks) about MER

Until Housing Improves, Don't Expect Stocks to Rebound
by J.D. Steinhilber (Agile Investing) about SPY

Google Blows Q2: Multiple Compression to Continue
by Henry Blodget about GOOG

... more »

TODAY'S TOP PICKS

DNDN		Cancer Vaccines: Investing Opportunities beyond Dendreon (NASDAQ: D... by Mike Havrilla
CLDA		BioMed Research Reports: Clinical Data (NASDAQ: CLDA), Lpath (OTC: ... by Mike Havrilla
PARD		Biotech Stocks - Beware of The Covered Call Trap by Ivan Mutaftchiev
PBIO		Under the Radar Healthcare Stocks: Protox, Pressure BioSciences, Un... by Mike Havrilla
ISIS		ISIS - Last Tuesday's Drop Presents a Nice Buy Opportunity by Ivan Mutaftchiev

... more »

StreetInsider.com on VRTX

Visit streetinsider.com

Discussion Wall

+ Add

Be the first to start a discussion and earn 2 points.

... more »

More Resources

About Vertex Pharmaceuticals Inc - Answers.com

Historical Prices - Yahoo

Message Boards - BoardCentral.com

More Info: Yahoo | Google | Reuters

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.